Fukushima A, Nishino K, Yoshida O, Ueno H
Department of Ophthalmology, Kochi Medical School, Nankoku, Japan.
Curr Eye Res. 1998 Aug;17(8):763-9.
We recently reported the essential role of cellular immunity on the induction of experimental immune-mediated blepharoconjunctivitis (EC, formerly EAC) by using ovalbumin (OVA) as a model antigen in Lewis rats. The purpose of this study was to investigate the possible induction of EC by immunization with an OVA peptide (OVA 323-339).
Lewis rats were immunized with various doses of OVA or OVA 323-339 in complete Freund's adjuvant. Three weeks later they were challenged with OVA or OVA 323-339 by eye drops; 24 h after challenge, eyes including lids, lymph nodes and blood were harvested after clinical evaluation. An OVA 323-339-specific cell line (S816) was established by periodical stimulation with this peptide. Pathogenicity of S816 was tested by adoptive transfer of S816 into syngeneic recipient rats after challenge with OVA or OVA 323-339.
All rats immunized with OVA 323-339 developed EC after challenge with OVA or OVA 323-339. Rats immunized with OVA 323-339 at doses as low as 0.01 microg had severe clinical scores. OVA-primed rats also developed EC after challenge with OVA 323-339. OVA-primed lymph node cells responded to OVA but not to OVA 323-339. OVA 323-339-primed lymph node cells responded to OVA 323-339 but not to OVA and produced IFN-gamma by stimulation with either OVA or OVA 323-339 (three- to fourfold more than with OVA-primed lymph node cells). Recipient rats of S816 developed severe EC after challenge with either OVA or OVA 323-339.
OVA 323-339 was identified as a potent pathogenic peptide in EC.
我们最近报道了细胞免疫在以卵清蛋白（OVA）作为Lewis大鼠模型抗原诱导实验性免疫介导性睑结膜炎（EC，原称EAC）中的重要作用。本研究的目的是调查用OVA肽（OVA 323 - 339）免疫是否可能诱导EC。
用不同剂量的OVA或OVA 323 - 339在完全弗氏佐剂中免疫Lewis大鼠。三周后，通过滴眼用OVA或OVA 323 - 339对其进行攻击；攻击后24小时，在临床评估后收集包括眼睑、淋巴结和血液在内的眼睛样本。通过用该肽定期刺激建立了OVA 323 - 339特异性细胞系（S816）。在用OVA或OVA 323 - 339攻击后，通过将S816过继转移到同基因受体大鼠中来测试S816的致病性。
所有用OVA 323 - 339免疫的大鼠在用OVA或OVA 323 - 339攻击后均发生了EC。用低至0.01微克OVA 323 - 339免疫的大鼠具有严重的临床评分。用OVA预致敏的大鼠在用OVA 323 - 339攻击后也发生了EC。用OVA预致敏的淋巴结细胞对OVA有反应，但对OVA 323 - 339无反应。用OVA 323 - 339预致敏的淋巴结细胞对OVA 323 - 339有反应，但对OVA无反应，并且在用OVA或OVA 323 - 339刺激时产生干扰素-γ（比用OVA预致敏的淋巴结细胞多三到四倍）。S816的受体大鼠在用OVA或OVA 323 - 339攻击后发生了严重的EC。
OVA 323 - 339被确定为EC中的一种强效致病肽。
